Trade Veracyte Inc - VCYT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Veracyte Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 22.27 |
Open* | 22.07 |
1-Year Change* | 33.11% |
Day's Range* | 21.67 - 22.12 |
52 wk Range | 14.92-32.40 |
Average Volume (10 days) | 452.48K |
Average Volume (3 months) | 12.42M |
Market Cap | 1.84B |
P/E Ratio | -100.00K |
Shares Outstanding | 72.75M |
Revenue | 328.63M |
EPS | -0.40 |
Dividend (Yield %) | N/A |
Beta | 1.32 |
Next Earnings Date | Oct 31, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 29, 2023 | 22.27 | -0.71 | -3.09% | 22.98 | 23.37 | 22.14 |
Sep 28, 2023 | 22.85 | -0.02 | -0.09% | 22.87 | 23.41 | 22.33 |
Sep 27, 2023 | 22.83 | 0.65 | 2.93% | 22.18 | 23.06 | 22.18 |
Sep 26, 2023 | 22.55 | 0.33 | 1.49% | 22.22 | 23.04 | 22.22 |
Sep 25, 2023 | 22.44 | 0.22 | 0.99% | 22.22 | 22.73 | 22.02 |
Sep 22, 2023 | 22.45 | -0.20 | -0.88% | 22.65 | 22.84 | 22.12 |
Sep 21, 2023 | 22.55 | -0.42 | -1.83% | 22.97 | 22.97 | 22.37 |
Sep 20, 2023 | 23.27 | -0.88 | -3.64% | 24.15 | 24.41 | 23.27 |
Sep 19, 2023 | 24.08 | -0.04 | -0.17% | 24.12 | 24.44 | 23.57 |
Sep 18, 2023 | 24.28 | -0.56 | -2.25% | 24.84 | 25.06 | 24.27 |
Sep 15, 2023 | 25.00 | -0.19 | -0.75% | 25.19 | 25.24 | 24.69 |
Sep 14, 2023 | 25.16 | -0.20 | -0.79% | 25.36 | 25.53 | 24.85 |
Sep 13, 2023 | 25.32 | 0.08 | 0.32% | 25.24 | 25.96 | 25.24 |
Sep 12, 2023 | 25.23 | 0.16 | 0.64% | 25.07 | 25.63 | 24.97 |
Sep 11, 2023 | 25.25 | 0.56 | 2.27% | 24.69 | 25.40 | 24.59 |
Sep 8, 2023 | 24.64 | -0.56 | -2.22% | 25.20 | 25.35 | 24.58 |
Sep 7, 2023 | 25.28 | -0.05 | -0.20% | 25.33 | 25.65 | 25.17 |
Sep 6, 2023 | 25.98 | 0.42 | 1.64% | 25.56 | 26.41 | 25.56 |
Sep 5, 2023 | 26.15 | -0.09 | -0.34% | 26.24 | 26.62 | 26.00 |
Sep 1, 2023 | 26.65 | -0.04 | -0.15% | 26.69 | 27.16 | 26.22 |
Veracyte Inc Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, October 31, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 Veracyte Inc Earnings Release Q3 2023 Veracyte Inc Earnings ReleaseForecast -Previous - |
Tuesday, February 20, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 Veracyte Inc Earnings Release Q4 2023 Veracyte Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 296.536 | 219.514 | 117.483 | 120.368 | 92.008 |
Revenue | 296.536 | 219.514 | 117.483 | 120.368 | 92.008 |
Cost of Revenue, Total | 101.582 | 74.4 | 41.455 | 36.523 | 33.078 |
Gross Profit | 194.954 | 145.114 | 76.028 | 83.845 | 58.93 |
Total Operating Expense | 337.617 | 301.417 | 152.872 | 135.495 | 114.241 |
Selling/General/Admin. Expenses, Total | 168.533 | 134.843 | 87.585 | 81.312 | 63.623 |
Research & Development | 40.079 | 29.531 | 16.962 | 14.564 | 14.42 |
Depreciation / Amortization | 24.123 | 18.143 | 6.87 | 3.096 | 3.12 |
Operating Income | -41.081 | -81.903 | -35.389 | -15.127 | -22.233 |
Interest Income (Expense), Net Non-Operating | 1.971 | -1.187 | -0.229 | -0.677 | -1.963 |
Other, Net | 2.683 | 1.441 | 0.709 | 3.205 | 1.197 |
Net Income Before Taxes | -36.427 | -81.649 | -34.909 | -12.599 | -22.999 |
Net Income After Taxes | -36.56 | -75.563 | -34.909 | -12.599 | -22.999 |
Net Income Before Extra. Items | -36.56 | -75.563 | -34.909 | -12.599 | -22.999 |
Net Income | -36.56 | -75.563 | -34.909 | -12.599 | -22.999 |
Income Available to Common Excl. Extra. Items | -36.56 | -75.563 | -34.909 | -12.599 | -22.999 |
Income Available to Common Incl. Extra. Items | -36.56 | -75.563 | -34.909 | -12.599 | -22.999 |
Diluted Net Income | -36.56 | -75.563 | -34.909 | -12.599 | -22.999 |
Diluted Weighted Average Shares | 71.5492 | 67.8903 | 53.2392 | 46.1382 | 37.0202 |
Diluted EPS Excluding Extraordinary Items | -0.51098 | -1.11302 | -0.6557 | -0.27307 | -0.62125 |
Diluted Normalized EPS | -0.481 | -0.90142 | -0.6557 | -0.27307 | -0.62125 |
Total Extraordinary Items | |||||
Dividends per Share - Common Stock Primary Issue | |||||
Unusual Expense (Income) | 3.3 | 22.1 | |||
Other Operating Expenses, Total | 22.4 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 90.322 | 82.422 | 80.297 | 75.592 | 72.864 |
Revenue | 90.322 | 82.422 | 80.297 | 75.592 | 72.864 |
Cost of Revenue, Total | 29.688 | 26.229 | 26.831 | 26.008 | 25.03 |
Gross Profit | 60.634 | 56.193 | 53.466 | 49.584 | 47.834 |
Total Operating Expense | 98.373 | 92.92 | 85.717 | 85.272 | 83.597 |
Selling/General/Admin. Expenses, Total | 50.051 | 46.481 | 41.688 | 42.731 | 39.964 |
Research & Development | 12.268 | 12.606 | 11.123 | 10.647 | 9.256 |
Depreciation / Amortization | 6.366 | 6.204 | 6.075 | 5.886 | 6.047 |
Unusual Expense (Income) | 1.4 | 0 | 3.3 | ||
Other Operating Expenses, Total | |||||
Operating Income | -8.051 | -10.498 | -5.42 | -9.68 | -10.733 |
Interest Income (Expense), Net Non-Operating | 1.173 | 1.411 | 2.013 | -0.085 | -0.223 |
Other, Net | -1.399 | 0.996 | -0.034 | 0.89 | 1.309 |
Net Income Before Taxes | -8.277 | -8.091 | -3.441 | -8.875 | -9.647 |
Net Income After Taxes | -8.402 | -8.091 | -3.844 | -8.723 | -9.532 |
Net Income Before Extra. Items | -8.402 | -8.091 | -3.844 | -8.723 | -9.532 |
Net Income | -8.402 | -8.091 | -3.844 | -8.723 | -9.532 |
Income Available to Common Excl. Extra. Items | -8.402 | -8.091 | -3.844 | -8.723 | -9.532 |
Income Available to Common Incl. Extra. Items | -8.402 | -8.091 | -3.844 | -8.723 | -9.532 |
Diluted Net Income | -8.402 | -8.091 | -3.844 | -8.723 | -9.532 |
Diluted Weighted Average Shares | 72.4787 | 72.1755 | 71.8288 | 71.6567 | 71.477 |
Diluted EPS Excluding Extraordinary Items | -0.11592 | -0.1121 | -0.05352 | -0.12173 | -0.13336 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.11592 | -0.0927 | -0.05352 | -0.12173 | -0.10335 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 248.636 | 243.102 | 375.679 | 187.687 | 96.952 |
Cash and Short Term Investments | 178.852 | 173.197 | 349.364 | 159.317 | 77.995 |
Cash & Equivalents | 154.247 | 173.197 | 349.364 | 159.317 | 77.995 |
Total Receivables, Net | 44.021 | 41.461 | 18.461 | 19.329 | 13.168 |
Accounts Receivable - Trade, Net | 44.021 | 41.461 | 18.461 | 19.329 | 13.168 |
Total Inventory | 14.294 | 11.225 | 4.657 | 6.806 | 3.402 |
Prepaid Expenses | 11.469 | 17.219 | 3.197 | 2.235 | 2.387 |
Other Current Assets, Total | |||||
Total Assets | 1156.42 | 1187.82 | 457.163 | 275.212 | 120.638 |
Property/Plant/Equipment, Total - Net | 30.862 | 31.141 | 16.833 | 17.741 | 8.94 |
Property/Plant/Equipment, Total - Gross | 56.844 | 52.622 | 33.23 | 31.821 | 20.946 |
Accumulated Depreciation, Total | -25.982 | -21.481 | -16.397 | -14.08 | -12.006 |
Goodwill, Net | 695.891 | 707.904 | 2.725 | 2.725 | 1.057 |
Intangibles, Net | 174.866 | 202.731 | 59.924 | 65.019 | 12 |
Other Long Term Assets, Total | 6.167 | 2.947 | 2.002 | 2.04 | 1.689 |
Total Current Liabilities | 62.614 | 64.151 | 16.781 | 17.469 | 13.059 |
Accounts Payable | 11.911 | 12.36 | 3.116 | 2.328 | 2.516 |
Accrued Expenses | 41.844 | 43.105 | 13.294 | 15.141 | 9.186 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 8.859 | 7.559 | 0.371 | ||
Total Liabilities | 81.222 | 91.311 | 35.931 | 35.757 | 40.883 |
Total Long Term Debt | 0.4 | 0.6 | 0.81 | 0.694 | 23.925 |
Long Term Debt | 0 | 0.81 | 0.694 | 23.925 | |
Capital Lease Obligations | 0.4 | 0.6 | 0 | ||
Other Liabilities, Total | 13.677 | 20.968 | 18.34 | 17.594 | 3.899 |
Total Equity | 1075.2 | 1096.51 | 421.232 | 239.455 | 79.755 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.072 | 0.071 | 0.058 | 0.05 | 0.041 |
Additional Paid-In Capital | 1500.19 | 1468.68 | 702.768 | 486.09 | 313.8 |
Retained Earnings (Accumulated Deficit) | -393.717 | -357.157 | -281.594 | -246.685 | -234.086 |
Total Liabilities & Shareholders’ Equity | 1156.42 | 1187.82 | 457.163 | 275.212 | 120.638 |
Total Common Shares Outstanding | 71.9594 | 71.1231 | 58.2005 | 49.6253 | 40.8632 |
Current Port. of LT Debt/Capital Leases | 0 | 1.127 | 0 | 1.357 | |
Deferred Income Tax | 4.531 | 5.592 | |||
Other Equity, Total | -31.346 | -15.083 | |||
Short Term Investments | 24.605 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 251.503 | 248.636 | 238.516 | 235.045 | 238.483 |
Cash and Short Term Investments | 177.89 | 178.852 | 170.112 | 163.998 | 163.615 |
Cash & Equivalents | 177.89 | 154.247 | 170.112 | 153.447 | 163.615 |
Total Receivables, Net | 45.489 | 44.021 | 40.068 | 40.448 | 42.481 |
Accounts Receivable - Trade, Net | 45.489 | 44.021 | 40.068 | 40.448 | 42.481 |
Total Inventory | 13.306 | 14.294 | 13.798 | 14.6 | 12.372 |
Prepaid Expenses | 14.818 | 11.469 | 14.538 | 15.999 | 20.015 |
Total Assets | 1157.12 | 1156.42 | 1125.96 | 1144.2 | 1173.59 |
Property/Plant/Equipment, Total - Net | 29.38 | 30.862 | 31.122 | 32.004 | 31.962 |
Goodwill, Net | 699.718 | 695.891 | 676.885 | 690.04 | 704.368 |
Intangibles, Net | 170.226 | 174.866 | 176.542 | 184.367 | 196.228 |
Other Long Term Assets, Total | 6.292 | 6.167 | 2.892 | 2.742 | 2.548 |
Total Current Liabilities | 55.993 | 62.614 | 58.352 | 59.345 | 62.543 |
Accounts Payable | 15.655 | 11.911 | 11.114 | 10.328 | 11.273 |
Accrued Expenses | 34.717 | 41.844 | 36.095 | 37.495 | 42.392 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 5.621 | 8.859 | 9.956 | 10.389 | 7.799 |
Total Liabilities | 75.86 | 81.222 | 77.78 | 80.047 | 88.399 |
Total Long Term Debt | 0.2 | 0.4 | 0.5 | 0.6 | 0.6 |
Long Term Debt | |||||
Deferred Income Tax | 4.594 | 4.531 | 4.342 | 4.605 | 4.983 |
Other Liabilities, Total | 15.073 | 13.677 | 14.586 | 15.497 | 20.273 |
Total Equity | 1081.26 | 1075.2 | 1048.18 | 1064.15 | 1085.19 |
Common Stock | 0.072 | 0.072 | 0.072 | 0.072 | 0.071 |
Additional Paid-In Capital | 1509.86 | 1500.19 | 1492.04 | 1483.28 | 1477.42 |
Retained Earnings (Accumulated Deficit) | -401.808 | -393.717 | -389.873 | -381.15 | -371.618 |
Total Liabilities & Shareholders’ Equity | 1157.12 | 1156.42 | 1125.96 | 1144.2 | 1173.59 |
Total Common Shares Outstanding | 72.3831 | 71.9594 | 71.7415 | 71.5585 | 71.4329 |
Capital Lease Obligations | 0.2 | 0.4 | 0.5 | 0.6 | 0.6 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Other Equity, Total | -26.866 | -31.346 | -54.066 | -38.05 | -20.681 |
Current Port. of LT Debt/Capital Leases | 0 | 1.187 | 1.133 | 1.079 | |
Short Term Investments | 0 | 24.605 | 0 | 10.551 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -36.56 | -75.563 | -34.909 | -12.599 | -22.999 |
Cash From Operating Activities | 7.535 | -31.621 | -9.711 | -3.232 | -13.521 |
Cash From Operating Activities | 25.928 | 19.593 | 7.944 | 4.117 | 3.92 |
Non-Cash Items | 34.415 | 26.388 | 17.735 | 10.096 | 6.209 |
Cash Taxes Paid | 0.57 | 0.112 | 0.112 | 0.035 | 0.079 |
Cash Interest Paid | 0.009 | 0.009 | 0.013 | 0.332 | 1.547 |
Changes in Working Capital | -16.381 | 4.219 | -0.481 | -4.846 | -0.651 |
Cash From Investing Activities | -29.387 | -739.206 | -3.837 | -42.733 | -1.874 |
Capital Expenditures | -8.549 | -5.376 | -2.837 | -2.756 | -1.874 |
Other Investing Cash Flow Items, Total | -20.838 | -733.83 | -1 | -39.977 | 0 |
Cash From Financing Activities | 3.494 | 596.32 | 203.595 | 127.287 | 59.499 |
Financing Cash Flow Items | -3.167 | -9.029 | -3.845 | 0 | 0.403 |
Issuance (Retirement) of Stock, Net | 7.942 | 605.349 | 207.54 | 152.495 | 59.388 |
Issuance (Retirement) of Debt, Net | -1.281 | 0 | -0.1 | -25.208 | -0.292 |
Net Change in Cash | -18.95 | -176.021 | 190.047 | 81.322 | 44.104 |
Deferred Taxes | 0.133 | -6.258 | |||
Foreign Exchange Effects | -0.592 | -1.514 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -8.091 | -36.56 | -32.716 | -23.993 | -14.461 |
Cash From Operating Activities | -2.172 | 7.535 | -2.209 | -9.235 | -8.872 |
Cash From Operating Activities | 6.67 | 25.928 | 19.372 | 13.048 | 6.556 |
Deferred Taxes | 0 | 0.133 | -0.27 | -0.118 | -0.003 |
Non-Cash Items | 9.71 | 34.415 | 27.388 | 18.315 | 7.447 |
Cash Interest Paid | 0.009 | 0 | 0 | 0 | |
Changes in Working Capital | -10.461 | -16.381 | -15.983 | -16.487 | -8.411 |
Cash From Investing Activities | 24.08 | -29.387 | -2.953 | -11.76 | -2.453 |
Capital Expenditures | -0.993 | -8.549 | -6.677 | -4.963 | -2.453 |
Other Investing Cash Flow Items, Total | 25.073 | -20.838 | 3.724 | -6.797 | 0 |
Cash From Financing Activities | 1.685 | 3.494 | 3.401 | 1.915 | 1.99 |
Financing Cash Flow Items | -2.277 | -3.167 | -2.639 | -1.865 | -1.447 |
Issuance (Retirement) of Stock, Net | 3.962 | 7.942 | 6.134 | 3.877 | 3.537 |
Issuance (Retirement) of Debt, Net | 0 | -1.281 | -0.094 | -0.097 | -0.1 |
Net Change in Cash | 23.643 | -18.95 | -3.085 | -19.75 | -9.582 |
Foreign Exchange Effects | 0.05 | -0.592 | -1.324 | -0.67 | -0.247 |
Cash Taxes Paid | 0.57 | -0.43 | 0.064 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Veracyte Inc Company profile
About Veracyte Inc
Veracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. It offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. It also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Veracyte Inc revenues increased 87% to $219.5M. Net loss increased from $34.9M to $75.6M. Revenues reflect United States segment increase of 83% to $201M, International segment increase from $7.9M to $18.5M. Higher net loss reflects Selling and marketing - Balancing value increase of 54% to $75.4M (expense), General & Administrative Expenses increase of 47% to $42.2M (expense).
Equity composition
Common Stock, $0.001 Par, 10/13, 125M auth., 20,989,890 issd., Insiders Own 76.17%
Industry: | Bio Diagnostics & Testing |
6000 Shoreline Court, Suite 300
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com